Results for tag: "Xolair"

Xolair (omalizumab) is a biologic drug used to treat moderate to severe allergic asthma and chronic idiopathic urticaria (hives). It is a monoclonal antibody that binds to immunoglobulin E (IgE), a type of antibody that plays a role in allergic reactions. Xolair works by blocking IgE from binding to mast cells, which are responsible for releasing histamine and other chemicals that cause allergic reactions. Xolair is administered as an injection every two to four weeks. Xolair is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2003. It is currently the only biologic drug approved for the treatment of allergic asthma and chronic idiopathic urticaria. Xolair is marketed by Genentech, a subsidiary of Roche, and Novartis. Other companies involved in the Xolair market include GlaxoSmithKline, Sanofi, and AstraZeneca. Show Less Read more